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Bipolar Radiofrequency Renal Denervation with the Vessix Catheter
in Patients with Resistant Hypertension: 2-year Results from the
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BACKGROUND The Vessix Renal Denervation System (Boston Scien-
tiﬁc, Marlborough, MA) consists of an over-the-wire low-pressure
balloon catheter with an array of bipolar radiofrequency electrodes.
Primary endpoint results of the REDUCE-HTN trial showed signiﬁcant
blood pressure reductions and a low major adverse event rate 6
months following treatment with the Vessix system. Ofﬁce blood
pressure measurements and safety monitoring continues through 2
years post-treatment.
METHODS The REDUCE-HTN trial is a prospective, multicenter, sin-
gle-arm study. Patients were required to have an ofﬁce-based systolic
blood pressure 160 mmHg despite treatment with 3 antihyperten-
sive medications at maximally tolerated doses.
RESULTS Among enrolled patients (N¼146), mean baseline ofﬁce blood
pressurewas 182.418.4/100.114.0mmHgandambulatory bloodpressure
was 152.915.2/87.513.3 mmHg. Among 94 patients with 18 month data,
mean ofﬁce blood pressure was reduced to 157.224.6/86.914.8mmHg; a
reduction of 27.120.4/11.211.4 mmHg (P<.0001). Eighty percent of those
(75/94) responded to treatment with a reduction in ofﬁce systolic blood
pressure 10 mmHg at 18 months. The rate of procedure-related serious
adverse events was 5.6% at 6 months, with no new procedure- or device-
related serious adverse events reported between6 and 18months of follow-
up. Final 2-year efﬁcacy and safety data will be available at the time of
presentation.
CONCLUSIONS Eighteen-month data available to date from the
REDUCE-HTN study support the safety and efﬁcacy of renal dener-
vation with the Vessix system to treat resistant hypertension, with
potential for sustained blood pressure reductions through 2 years.
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Renal Denervation in the Treatment of Resistant Hypertension: A
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BACKGROUND Renal sympathetic denervation (RDN) has been
introduced as a possible treatment for resistant hypertension (RH);
however, the largest trial to date has shown little beneﬁt. Our aim was
to compare renal denervation versus pharmacological therapy in pa-
tients with resistant hypertension in eight trials.
METHODS We conducted a meta-analysis of prospective trials which
randomized patients with resistant hypertension to renal denervation
or pharmacological antihypertensive treatment alone and reported
the pre-speciﬁed outcomes. Mantel Haenszel relative risks and mean
differences were calculated using random effect models.
RESULTS Eight trials (N¼1011)met the inclusion criteria. At 6months RDN
was associated with greater reduction in 24-hour systolic blood pressure(SBP) (mean difference -3.21; 95% CI -5.19, -1.24; P¼0.001), and 24-hour
diastolic blood pressure (DBP) (mean difference -1.60; 95% CI -2.76, -0.44;
P¼0.007). RDN was also associated with a decrease in the number of anti-
hypertensive medications compared to the control arm (mean difference
-0.32; 95%CI -0.52, -0.11; P¼0.002).Themeandifference inchangebetween
RDNand controlwas -7.69mmHg for ofﬁce SBP (P¼0.18), and -4.54mmHg
for DBP (P¼0.009) favoring RDN. Sensitivity analysis including trials with
homogenous antihypertensivemedical treatment protocol among the RDN
andcontrols showedsigniﬁcant reductions inofﬁce systolic anddiastolicBP
at 6 months favoring RDN (mean difference -14.6; 95% CI -26.28, -2.92;
P¼0.01), (meandifference -6.06;95%CI -9.60, -2.53; P<0.001), respectively.
There was no signiﬁcant difference in terms of heart rate, kidney function,
myocardial infraction, stroke, or hypertensive emergency.CONCLUSIONS RDN is associated with signiﬁcant 24-hour ambula-
tory and ofﬁce based reduction in both systolic and diastolic blood
pressure compared to pharmacological treatment alone. Renal
denervation is safe and may have a potential role as an adjunct
treatment in patients with resistant hypertension.
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BACKGROUND Transcatheter renal denervation (RDN) therapy has
emerged as a therapeutic option for patients diagnosed hypertension
resistant to pharmacologic therapy. We aimed to evaluate the effects
of radiofrequency treatment (RF) delivered by the Terumo Iberis
catheter in a large animal model. Additionally, as a secondary end
point, we aimed to determine the safety implications of delivery of
one cycle versus two cycles of RF ablations.
METHODS 22 domestic swine were enrolled. 18 animals underwent RDN,
performed bilaterally; 4 remained untreated as naïve controls for norepi-
nephrine levels (NE) only. Renal arteries were randomized to receive a
single cycleof 120seconds (n¼24) treatment andwere followed for7, 30and
90 days. 8 renal arteries received 2 treatment cycles (240 seconds total) and
were followed for 7 days only. 3 arteries were untreated. Renal cortical
samples from the single-cycle treatment group were harvested for NE
evaluation at each timepoint.All renal arterieswereharvested forhistology
and immunohistochemical (IHC) evaluation.
RESULTS All renal arterieswere suitable forRF therapybyangiography.The
characteristic “notches” post-RF were observed in all treated arteries. At
follow up, all arteries demonstrated no luminal obstruction with a TIMI 3
ﬂow.TheNEassay showeda 70%decrease inNE levels (76.6857.87 ng/g) at
7 days post RDN, 81% signiﬁcant decrease at 30 days (49.0545.81 ng/g), and
51%decrease at 90 days (12.773.2 ng/g) compared to control (254.154.1 ng/
g). Histologically, the thermal effect in the perivascular tissue extended from
an average of 40% to a complete (100%) circumferential involvement with a
depthreachingupto8mm.TheprimaryhistologicalandIHCfeatureat 7days
was nerve necrosis with consequent nerve atrophy distal to the RF treated
level; the arterial wall showed complete re-endothelialization and hyalini-
zation of the media (thermal coagulation necrosis). At 30 days, necrosis was
no longer prominent and was replaced by healing changes of ﬁbrosis. Neu-
romatous regenerationwas apparent at 30days atRF treated levels, a change
characterized by disorganized sprouting of neuroid ﬁbers within the thick-
ened perineurium. At 90 days these features progressed to become more
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ferential extent of RF injury between one and two cycle treatment groups.
CONCLUSIONS The Terumo Iberis RDN system was demonstrated
to be safe following single or double-cycle RF ablation. NE decrease
following RDN was demonstrated at 7, 30, and 90 days compared to
naïve controls, suggesting efﬁcient nerve ablation with the device as
intended for human use.
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BACKGROUND The blood pressure (BP) response to renal denervation
(RDN) is highly variable. In addition, the changes in renal artery (RA)
dimensions induced by RDN have rarely been quantiﬁed and never
been related to BP changes.
METHODS We investigated RAs of 16 patients (7 females, 11 diabetics,
mean age 62.6 years) pre and post RDN (Symplicity Flex in 9 pts,
Symplicity Spyral in 7 pts; both Medtronic Inc) with intravascular ul-
trasound (Atlantis pro, Boston Scientiﬁc iLab). IVUS images were
analyzed with QCU-CMS research software (LUMC) yielding global
measures of RA size (RA vessel volume VV, lumen volume LV, wall
volume WV), and measures of most pronounced focal changes (min-
imum and maximum vessel area VA, lumen area LA and wall burden
WB) - Figure. Patients were followed with ofﬁce and 24 hour blood
pressure monitoring at month 1, 3, 6, and 12.
RESULTS Pre RDN, 24 hour BP was 153/88 mm Hg, mean number of
ablation points was 11.3 (SD 3.4). After 1, 3, 6, and 12 months, 24 hour
BP decreased by 12/7, 6/4, 17/9, and 21/11 mm Hg, respectively. RDN
induced a non-signiﬁcant decrease in RA vessel volume of 5.6 (SD 9.8)
%, a signiﬁcant decrease of RA lumen volume of 8.8 (SD 10.7)%, and a
non-signiﬁcant increase of RA wall volume of 6.1 (SD 10.9) %. Max and
min LA decreased signiﬁcantly by 7.3 (SD 9.4) and 10.5 (14.3) %,
respectively, as did min VA by 7.1 (12.5) %. Max vessel area and min
and max wall burden did not change signiﬁcantly. Women had smaller
RAs, which was related to their lower body height. Changes in RA size
were similar between men and women, as were changes in blood
pressure. ABPM-based BP change at 1 (SBP, DBP), 3 (SBP, DBP), 6 (DBP)
and 12 (DBP) months was signiﬁcantly and directly related to changes
in min LA and min VA (correlation coeffﬁcients 0.63-0.80, p-values
0.002-0.02). At 1 year, decrease in SBP was related to increase in wall
volume post RDN (r¼ -0.88, p¼0.004). Patients with a decrease in
minimal VA post RDN above the median had a signiﬁcantly better BP
response at 1 and 3 months. Patients with an increase in WV post RDN
had a signiﬁcantly better SBP response at 6 and 12 months.CONCLUSIONS RDN leads to effects on RA dimensions (decrease in
vessel and lumen size, increase in wall thickness), which can be
quantiﬁed by IVUS. A higher degree of changes may be associated
with a better BP response to the procedure.
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BACKGROUND Renal artery RF ablation is under investigation for the
treatment of hypertension. Recent research suggests lesion anatomic
placement may impact efﬁcacy of RF catheter renal ablation. Due to the
closer proximity of renal sympathetic nerves in the distal vessel segments,
it has been suggested that treatment of the renal artery branches might
help to reduce variability in efﬁcacy. However, it is unclear whether
focused distal treatment of the main renal artery is as effective as branchþ
main renal artery treatment. This study was initiated to investigate the
overall performance of two RF renal nerve ablation systems as well as
ablation anatomic location within the main renal and or bifurcations.
METHODS Sixteen swine were treated unilaterally with either 8 le-
sions in the branch renal arteries (BA) or 8 in the branch þ 4 in the
main renal artery (MA) with the Medtronic Spyral(TM) catheter (SP) or
in the MA alone with the St. Jude Medical EnligHTN(TM) catheter (EN)
in one of four arms: 1) SP8 - 8 BA lesions, 2) SP12 - 8 BA þ 4 MA lesions,
3) EN8 - 8 MA lesions, or 4) EN12 - 12 MA lesions. Treatment followed
manufacturers’ instructions for use & were performed by one proce-
duralist. All lesions in the MA were placed as distal as possible without
overlapping treatment sites. Animals were euthanized at 14 days with
each serving as its own control for norepinephrine (NE) analysis.
RESULTS A total of 162 lesions (EN n¼80 & SP n¼82) were created. All re-
sults are given asmean & StDev unless stated otherwise. Each arm showed
statistical signiﬁcant changes in NE (ng/g) between treated kidneys vs.
untreated contralateral control (C): EN8 125.0159.0 vs. EN8-C 461.284.1
(P¼0.010), EN12 22.9 14.7 vs. EN12-C 492.8 62.9 (P<0.001), SP8 106.1
78.4 vs. SP8-C 438.5 66.4 (P<0.001), SP12 72.5 79.8 vs. SP12-C 411.155
96.7 (P¼0.002). Therewereno statistically signiﬁcant differences in tissue
NE % reductions across each arm based on catheter, anatomic location, &
number of lesions: EN8 –74 34%, EN12 –95 3%, SP8 – 76 16%, SP12 –82
17% (P¼0.494). Nerve count based on anatomic location & lesion pathol-
ogy results will be presented.CONCLUSIONS There was no difference observed between the %
reduction in tissue NE levels comparing main renal artery distal
treatment with the EnligHTN catheter & branch þ main renal artery
treatment with the Spyral catheter.
